Disease · MONDO_0005155

cirrhosis of liver

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cirrhosis of liver. Diseases, record MONDO_0005155. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005155

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cirrhosis of liver; Open Targets
Open Targets ID: MONDO_0005155; Open Targets
Other names: CL - Cirrhosis of liver, Cirrhoses, Hepatic, Cirrhoses, Liver, Cirrhosis of liver (disorder), Cirrhosis of liver NOS, Cirrhosis of liver NOS (disorder), Cirrhosis of liver without mention of alcohol, Cirrhosis, Hepatic, Cirrhosis, Liver, Fibroses, Liver, Fibrosis, Liver, Hepatic Cirrhoses, Hepatic cirrhosis, Hepatic cirrhosis, NOS, Liver Cirrhoses, Liver Fibroses, Liver Fibrosis, Scar tissue replaces healthy tissue in the liver, cirrhosis, liver cirrhosis; Open Targets
Disease Ontology: DOID:5082; Disease Ontology
MeSH: D008103; MeSH
NCI Thesaurus: C2951; NCI Thesaurus
Highest stage of its drugs: Approval, for 9 of its 189 drugs, from DailyMed, EMA Human Drugs and PMDA; Open Targets

Drugs189

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RIBAVIRIN	CHEMBL1643	Small molecule	Approval	DailyMed	56	35	35	Drugs and targets
ALBUMIN HUMAN	CHEMBL1201451	Protein	Approval	PMDA	23	22	21	Drugs and targets
FUROSEMIDE	CHEMBL35	Small molecule	Approval	DailyMed	29	2	2	Drugs and targets
SPIRONOLACTONE	CHEMBL1393	Small molecule	Approval	DailyMed and EMA Human Drugs	6	2	2	Drugs and targets
SEMAGLUTIDE	CHEMBL2108724	Protein	Approval	EMA Human Drugs	3	2	2	Drugs and targets
RESMETIROM	CHEMBL3261331	Small molecule	Approval	EMA Human Drugs	2	1	1	Drugs and targets
HYDROCHLOROTHIAZIDE	CHEMBL435	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
ETHACRYNIC ACID	CHEMBL456	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
TRIAMTERENE	CHEMBL585	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
SOFOSBUVIR	CHEMBL1259059	Small molecule	Phase 3	ClinicalTrials.gov	21	21	21	Drugs and targets

1 to 10 of 189

See all 189 drugs

Targets230

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IFNAR1	Interferon alpha/beta receptor	5	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Phase 3	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	5	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Phase 3	https://conductscience.org/library/genes/3455	Drugs and targets
ADRA1A	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 2/3	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 2/3	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 2/3	https://conductscience.org/library/genes/146	Drugs and targets
ADRB1	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/154	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	4	Type-1 angiotensin II receptor agonist; Type-1 angiotensin II receptor antagonist	Phase 3	https://conductscience.org/library/genes/185	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	4	HMG-CoA reductase inhibitor	Phase 3	https://conductscience.org/library/genes/3156	Drugs and targets
NR1H4	Bile acid receptor	4	Bile acid receptor FXR agonist	Phase 3	https://conductscience.org/library/genes/9971	Drugs and targets

1 to 10 of 230

See all 230 targets

Trials260

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 15 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03028740	AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)	Phase 3	1,778	2022-03-10	Nonalcoholic Steatohepatitis	CENICRIVIROC	Its record names the disease	ClinicalTrials.gov
NCT02292706	A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection		1,609	2023-10-04	Hepatitis C Virus Infection	LEDIPASVIR, RIBAVIRIN, SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR	Its record names the disease	ClinicalTrials.gov
NCT00006164	Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment	Phase 3	1,050	2009-09-04	Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis	PEGINTERFERON ALFA-2A, RIBAVIRIN	Its record names the disease	ClinicalTrials.gov
NCT03439254	Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis	Phase 3	919	2023-10-23	Compensated Cirrhosis, Nonalcoholic Steatohepatitis	OBETICHOLIC ACID	Its record names the disease	ClinicalTrials.gov
NCT03053063	Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)	Phase 3	883	2020-05-07	Nonalcoholic Steatohepatitis	SELONSERTIB	Its record names the disease	ClinicalTrials.gov
NCT00048724	Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)	Phase 3	631	2009-06-11	Chronic Hepatitis C, Cirrhosis	PEGINTERFERON ALFA-2B	Its record names the disease	ClinicalTrials.gov
NCT01728324	Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2	Phase 3	496	2016-02-12	Hepatitis C, Chronic	DELEOBUVIR, FALDAPREVIR, RIBAVIRIN	Its record names the disease	ClinicalTrials.gov
NCT04971785	Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)	Phase 2	457	2025-11-26	Nonalcoholic Steatohepatitis	CILOFEXOR, FIRSOCOSTAT, SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT03449446	Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)	Phase 2	395	2020-12-03	Nonalcoholic Steatohepatitis	CILOFEXOR, FIRSOCOSTAT, SELONSERTIB	Its record names the disease	ClinicalTrials.gov
NCT01704755	A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis	Phase 3	381	2015-01-06	Chronic Hepatitis C Infection, Compensated Cirrhosis	DASABUVIR, OMBITASVIR, PARITAPREVIR, RIBAVIRIN, RITONAVIR	Its record names the disease	ClinicalTrials.gov

1 to 10 of 260

See all 260 trials

Comparisons in its trials57

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cenicriviroc 150 mg vs Placebo: deaths from any cause	6 of 1,185	2 of 593	1,778	NCT03028740	Trial comparisons
Cenicriviroc 150 mg vs Placebo: serious adverse events	159 of 1,180	70 of 589	1,769	NCT03028740	Trial comparisons
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Serious Adverse Events	175 of 517	155 of 533	1,050	NCT00006164	Trial comparisons
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Development of Hepatocellular Carcinoma (HCC)	13 of 517	16 of 533	1,050	NCT00006164	Trial comparisons
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Variceal Hemorrhage	5 of 517	11 of 533	1,050	NCT00006164	Trial comparisons
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Ascites	32 of 517	27 of 533	1,050	NCT00006164	Trial comparisons
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Presumed Hepatocellular Carcinoma (HCC)	10 of 517	9 of 533	1,050	NCT00006164	Trial comparisons
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Death From Any Cause	31 of 517	22 of 533	1,050	NCT00006164	Trial comparisons
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Spontaneous Bacterial Peritonitis	3 of 517	3 of 533	1,050	NCT00006164	Trial comparisons
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits	57 of 517	52 of 533	1,050	NCT00006164	Trial comparisons

1 to 10 of 57

See all 57 comparisons in its trials

Papers from its trials227

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38916482	RESULT	1	PubMed
35439567	RESULT	1	PubMed
35120736	RESULT	1	PubMed
33657293	RESULT	1	PubMed
33185364	RESULT	1	PubMed
32576140	RESULT	1	PubMed
32147362	RESULT	1	PubMed
31812510	RESULT	1	PubMed
31731005	RESULT	1	PubMed
31596729	RESULT	1	PubMed

1 to 10 of 227

See all 227 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005155

GET https://conductscience.org/api/diseases/v1/MONDO_0005155/drugs?page=2

API reference For AI assistants